Stimulated C-peptide secretion partially preserved with verapamil versus placebo at 52 weeks after diagnosis of type 1 diabetes<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, March 7, 2023 (HealthDay News) — Verapamil partially preserves stimulated C-peptide secretion at 52 weeks after diagnosis among children with newly diagnosed type 1 diabetes, according to a study published online Feb. 24 in the Journal of the American Medical Association<\/em>.<\/p>\n Gregory P. Forlenza, M.D., from the University of Colorado in Aurora, and colleagues examined the effect of verapamil on pancreatic beta cell function in children aged 7 to 17 years with newly diagnosed type 1 diabetes. Participants were randomly assigned to once-daily oral verapamil or placebo (47 and 41 patients, respectively); 83 participants completed the trial. The primary outcome was area under the curve values for C-peptide level stimulated by a mixed-meal tolerance test at 52 weeks from diabetes diagnosis.<\/p>\n The researchers found that the mean C-peptide area under the curve was 0.66 pmol\/mL at baseline and 0.65 pmol\/mL at 52 weeks in the verapamil group compared with 0.60 pmol\/mL at baseline and 0.44 pmol\/mL at 52 weeks in the placebo group, equating to a 30 percent higher C-peptide level with verapamil at 52 weeks. The percentage of patients with a 52-week peak C-peptide level of 0.2 pmol\/mL or greater was 95 and 71 percent in the verapamil and placebo groups, respectively. At 52 weeks, hemoglobin A1c was 6.6 and 6.9 percent in the verapamil and placebo groups, respectively. A nonserious adverse event considered to be related to treatment occurred in 17 and 20 percent of participants in the verapamil and placebo groups, respectively.<\/p>\n “Further studies are needed to determine the longitudinal durability of C-peptide improvement and the optimal length of therapy,” the authors write.<\/p>\n Several authors disclosed financial ties to pharmaceutical and medical device companies, including Medtronic, Tandem Diabetes Care, and Dexcom, which provided the devices used in the trial.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n